Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial

José Ramón Arribas(Hospital Universitario La Paz), José M. Gatell(Universitat de Barcelona), Pierre‐Marie Girard, Laurence Weiss(Université Paris Cité), Hernando Knobel(Hospital General de Granollers), Maria Martínez‐Rebollar(Hospital Clínic de Barcelona), Judit Pich(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Joaquín Portilla(Hospital General Universitario de Alicante Doctor Balmis), André Cabie, Josep Mallolas(Hospital Clínic de Barcelona), Fernando Dronda(Hospital Universitario Ramón y Cajal), Marta Montero, Peré Domingo(Hospital de Sant Pau), Daniel Podzamczer(Bellvitge University Hospital), Manuel Crespo(Vall d'Hebron Hospital Universitari), José Antonio Iribarren(Biogipuzkoa Health Research Institute), Roland Landman, Federico Pulido(Bellvitge University Hospital), Francisco Zamora(Hospital Universitario La Paz), Vicente Estrada(Instituto de Salud Carlos III)
The Lancet Infectious Diseases
June 7, 2015
Cited by 143


Related Papers